CTNM trades 112.9% below Wall Street's consensus target of $19.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CTNM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Contineum Therapeutics, Inc. (CTNM) has a Wall Street consensus price target of $19.67, based on estimates from 4 covering analysts. With the stock currently trading at $9.24, this represents a potential upside of +112.9%. The company has a market capitalization of $345M.
Analyst price targets range from a low of $17.00 to a high of $23.00, representing a 31% spread in expectations. The median target of $19.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, CTNM trades at a trailing P/E of -5.6x. Analysts expect EPS to grow -5.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
IMVTImmunovant, Inc. | $6.8B | $33.17 | $40.00 | +20.6% | Buy | — | 23 |
PRTAProthena Corporation plc | $437M | $8.35 | $30.00 | +259.3% | Buy | 70.4x | 28 |
ARQTArcutis Biotherapeutics, Inc. | $3.5B | $27.61 | $41.80 | +51.4% | Buy | 66.9x | 12 |
KYMRKymera Therapeutics, Inc. | $10.0B | $121.13 | $141.53 | +16.8% | Buy | — | 27 |
ACADACADIA Pharmaceuticals Inc. | $3.1B | $17.83 | $30.05 | +68.5% | Buy | 28.6x | 37 |
INVAInnoviva, Inc. | $1.4B | $18.40 | $38.00 | +106.5% | Buy | 7.6x | 11 |
PTGXProtagonist Therapeutics, Inc. | $8.2B | $127.16 | $177.25 | +39.4% | Buy | 27.1x | 26 |
RXRXRecursion Pharmaceuticals, Inc. | $1.5B | $2.83 | $5.90 | +108.8% | Hold | — | 10 |
CRLCharles River Laboratories International, Inc. | $16.1B | $333.25 | $308.36 | -7.5% | Buy | 29.3x | 37 |
MEDPMedpace Holdings, Inc. | $18.1B | $646.87 | $646.90 | +0.0% | Hold | 35.5x | 19 |
Quick answers to the most common questions about buying CTNM stock.
The consensus Wall Street price target for CTNM is $19.67, representing 112.9% upside from the current price of $9.24. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CTNM has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $19.67 implies 112.9% upside from current levels.
CTNM's current price is $9.24 with a consensus target of $19.67 (112.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $23 for CTNM, while the most conservative target is $17. The consensus of $19.67 represents the median expectation. These targets typically reflect 12-month expectations.
CTNM is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CTNM stock forecast based on 4 Wall Street analysts shows a consensus price target of $19.67, with estimates ranging from $17 (bear case) to $23 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CTNM, with a "Buy" consensus rating and $19.67 price target (112.9% upside). 2 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CTNM analyst price targets range from $17 to $23, a 31% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19.67 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.